Hematopoietic Stem Cell Transplantation
Immunology·MeSH: Myelodysplastic Syndromes
Prevalence
0.5 / 100K
5 drugs in development·3 companies·4 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| nomacopan | Akari Therapeutics Plc (AKTX) |
Phase 1(1)
| Drug | Company |
|---|---|
| Veto Cell | Cell Source, Inc. (CLCS) |
Preclinical(1)
| Drug | Company |
|---|---|
| Veto Cell technology | Cell Source, Inc. (CLCS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Hematopoietic Stem Cell Transplantation?
BioSniper tracks 5 drugs in development for Hematopoietic Stem Cell Transplantation across 3 companies.
How many clinical trials target Hematopoietic Stem Cell Transplantation?
There are 4 clinical trials targeting Hematopoietic Stem Cell Transplantation tracked by BioSniper.
What is the prevalence of Hematopoietic Stem Cell Transplantation?
The estimated prevalence of Hematopoietic Stem Cell Transplantation is approximately 0.5 per 100,000 population.
Deep-dive into Hematopoietic Stem Cell Transplantation
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis